Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.00 Average PT from Analysts

Key Points

• Agios Pharmaceuticals has received a consensus rating of “Moderate Buy” from eight research firms, with a price target averaging $56.00.
• The company reported a loss of $1.93 per share for the last quarter, missing estimates, despite achieving $12.50 million in revenue, exceeding expectations.
• Recent insider transactions include significant share sales by CEO Brian Goff and insider Tsveta Milanova, decreasing their respective ownership by 15.07% and 9.59%.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $56.00.

Several analysts have recently issued reports on AGIO shares. Scotiabank decreased their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. Bank of America decreased their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $56.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 4th.

Agios Pharmaceuticals Stock Performance

Shares of AGIO traded down $0.30 during mid-day trading on Friday, hitting $36.42. 621,660 shares of the stock were exchanged, compared to its average volume of 753,277. The company has a market cap of $2.12 billion, a PE ratio of 3.31 and a beta of 0.87. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The firm has a 50-day moving average of $37.69 and a two-hundred day moving average of $33.30.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The firm had revenue of $12.50 million for the quarter, compared to analysts' expectations of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. On average, sell-side analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Activity at Agios Pharmaceuticals

In related news, Director David Scadden sold 1,400 shares of the stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $40.00, for a total transaction of $56,000.00. Following the sale, the director owned 17,603 shares in the company, valued at approximately $704,120. This represents a 7.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Tsveta Milanova sold 2,770 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $92,905.80. Following the sale, the insider owned 26,122 shares in the company, valued at $876,131.88. The trade was a 9.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 65,994 shares of company stock worth $2,341,232 in the last ninety days. Corporate insiders own 4.30% of the company's stock.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of AGIO. GF Fund Management CO. LTD. purchased a new stake in Agios Pharmaceuticals during the 4th quarter valued at $39,000. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at $40,000. CWM LLC grew its position in Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 996 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Agios Pharmaceuticals by 16.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 320 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after acquiring an additional 499 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.